Feng Qun, Huang Zhiyan, Su Lingjin, Fan Yulan, Guan Yongxia, Zhang Guimin
Lunan Pharmaceutical Group Co., Ltd., State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Linyi 276006, China.
Lunan Hope Pharmaceutical Co., Ltd., Linyi 276006, China.
Phytomedicine. 2022 Jun;100:154051. doi: 10.1016/j.phymed.2022.154051. Epub 2022 Mar 16.
Yinzhihuang granule, consisting of extracts of Artemisia capillaris Thunb., Gardenia jasminoides Ellis, Lonicera japonica Thunb., and Scutellaria baicalensis Georgi is a well-known traditional Chinese patent medicine for patients with liver injury in China. However, the effects and safety of its use for pathologic jaundice in newborns require further systematic evaluation.
To systematically evaluate the efficacy and safety of Yinzhihuang granules for the treatment of neonatal pathologic jaundice and to provide clinical evidence.
Chinese databases (China Network Knowledge Infrastructure, Wan Fang Database, and VIP Database) and English databases (PubMed, EmBase, and the Cochrane Library) were thoroughly investigated through screening randomized controlled trials on Yinzhihuang granules for neonatal pathologic jaundice from the establishment of all databases to November 18, 2021. A meta-analysis was performed for selected data using STATA software. TSA software was used for trial sequential analyses of the total effective rate and adverse reactions.
A total of 19 trials and 2,221 newborns with pathologic jaundice were included in this study. Outcome measures of clinical efficacy in the experimental group were higher than in controls, including total bilirubin (WMD = -30.34, 95% CI = -35.44 to -25.23, p < 0.001), direct bilirubin (WMD = -15.03, 95% CI = -23.54 to -6.52, p < 0.001), indirect bilirubin (WMD = -11.22, 95% CI = -17.50 to -4.95, p < 0.001), recovery time (WMD = -2.96, 95% CI = -3.92 to -2.00, p < 0.001), hospitalization time (WMD = -3.83, 95% CI = -4.89 to -2.76, p < 0.001), and liver function indices. There were statistically significant differences between the two groups. Likewise, the incidence of adverse reactions, including diarrhea, erythra, and fever decreased remarkably in the trial group (RR = 0.44, 95% CI = 0.33 to 0.59, p < 0.001). Publication bias did not exist. We verified the efficacy and safety of Yinzhihuang granules with phototherapy for pathologic jaundice in newborns according using TSA analysis.
Yinzhihuang granules with phototherapy for neonatal pathologic jaundice are more effective than phototherapy alone. The incidence of ADRs does not increase with the application of Yinzhihuang granules. Due to the heterogeneity across the included studies, additional multicenter clinical trials with follow-ups are needed to confirm our findings.
茵栀黄颗粒由茵陈、栀子、金银花、黄芩提取物组成,是中国治疗肝损伤患者的一种知名中成药。然而,其用于新生儿病理性黄疸的疗效和安全性需要进一步系统评价。
系统评价茵栀黄颗粒治疗新生儿病理性黄疸的疗效和安全性,为临床提供证据。
通过检索中国知网、万方数据库、维普数据库等中文数据库以及PubMed、EmBase、Cochrane图书馆等英文数据库,筛选自建库至2021年11月18日关于茵栀黄颗粒治疗新生儿病理性黄疸的随机对照试验。使用STATA软件对入选数据进行Meta分析。使用TSA软件对总有效率和不良反应进行试验序贯分析。
本研究共纳入19项试验,2221例病理性黄疸新生儿。试验组临床疗效指标高于对照组,包括总胆红素(WMD=-30.34,95%CI=-35.44至-25.23,p<0.001)、直接胆红素(WMD=-15.03,95%CI=-23.54至-6.52,p<0.001)、间接胆红素(WMD=-11.22,95%CI=-17.50至-4.95,p<0.001)、恢复时间(WMD=-2.96,95%CI=-3.92至-2.00,p<0.001)、住院时间(WMD=-3.83,95%CI=-4.89至-2.76,p<0.001)及肝功能指标。两组间差异有统计学意义。同样,试验组腹泻、皮疹、发热等不良反应发生率显著降低(RR=0.44,95%CI=0.33至0.59,p<0.001)。不存在发表偏倚。通过TSA分析验证了茵栀黄颗粒联合光疗治疗新生儿病理性黄疸的疗效和安全性。
茵栀黄颗粒联合光疗治疗新生儿病理性黄疸比单纯光疗更有效。应用茵栀黄颗粒不会增加不良反应发生率。由于纳入研究存在异质性,需要更多多中心随访临床试验来证实本研究结果。